Determinants of long-term protection after hepatitis b vaccination in infancy: A meta-analysis

Pediatric Infectious Disease Journal

Volumn 32, Issue 4, 2013, Pages 307-313

  Schönberger, Katharina ^a   Riedel, Christina ^a   Rückinger, Simon ^a   Mansmann, Ulrich ^a   Jilg, Wolfgang ^b   Kries, Rüdiger V ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Booster; Determinants of protection; Hepatitis B; Infant vaccination; Long term protection

Indexed keywords

HEPATITIS B VACCINE;

ANTIBODY TITER; ARTICLE; COCHRANE LIBRARY; EMBASE; FOLLOW UP; HEPATITIS B; HUMAN; LONG TERM CARE; MEDLINE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGENY; PROGNOSIS; PROTECTION; RECOMMENDED DRUG DOSE; SEROPREVALENCE; SYSTEMATIC REVIEW; VACCINATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNOLOGIC MEMORY; INFANT; MALE; MODELS, STATISTICAL; SEROEPIDEMIOLOGIC STUDIES; TIME FACTORS; VACCINATION; YOUNG ADULT;

EID: 85027954649     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31827bd1b0     Document Type: Article

References (74)

1. Bialek SR, Bower WA, Novak R, et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J. 2008;27:881-885.
2. Chaves SS, Groeger J, Helgenberger L, et al. Improved anamnestic response among adolescents boosted with a higher dose of the hepatitis B vaccine. Vaccine. 2010;28:2860-2864.
3. Coursaget P, Leboulleux D, Soumare M, et al. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J Hepatol. 1994;21: 250-254.
4. Da Villa G, Pelliccia MG, Peluso F, et al. Anti-HBs responses in children vaccinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine. Res Virol. 1997;148:109-114.
5. Lee PI, Lee CY, Huang LM, et al. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J Pediatr. 1995;126(5 Pt 1):716-721.
6. Gonzalez ML, Gonzalez JB, Salva F, et al. A 7-year follow-up of newborns vaccinated against hepatitis B. Vaccine. 1993;11:1033-1036.
7. Huang LM, Chiang BL, Lee CY, et al. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology. 1999;29:954-959.
8. Kao JT, Wang JH, Hung CH, et al. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. Vaccine. 2009;27:1858-1862.
9. Roznovsky L, Orsagova I, Kloudova A, et al. Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up. Infection. 2010;38:395-400.
10. van der Sande MA, Waight P, Mendy M, et al. Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis. 2006;193:1528-1535.
11. Wu JS, Hwang LY, Goodman KJ, et al. Hepatitis B vaccination in high-risk infants: 10-year follow-up. J Infect Dis. 1999;179:1319-1325.
12. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet. 2000;355: 561-565.
13. Viral Hepatitis Prevention Board. Meeting News. Viral Hepatitis. 2012;20:1-28.
14. Leuridan E, Van Damme P Hepatitis B and the need for a booster dose. Clin Infect Dis. 2011;53:68-75.
15. World Health Organization Publication. Hepatitis B vaccines: WHO position paper-recommendations. Vaccine. 2010;28:589-590.
16. Wenzel JJ, Jilg W Loss of antibodies, but not of protection. Lancet Infect Dis. 2010;10:738-739.
17. World Health Organization. Hepatitis B vaccines. Wkly Epidemiol Rec. 2009;84:405-419.
18. Hassan S, Ziba F Antibody titer in Iranian children 6 years after hepatitis B vaccine administration. Vaccine. 2007;25:3511-3514.
19. Lin CC, Yang CY, Shih CT, et al. Waning immunity and booster responses in nursing and medical technology students who had received plasma-derived or recombinant hepatitis B vaccine during infancy. Am J Infect Control. 2011;39:408-414.
20. Lu CY, Ni YH, Chiang BL, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis. 2008;197:1419-1426.
21. Resti M, Azzari C, Mannelli F, et al. Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections indicated? Vaccine. 1997;15:1338-1340.
22. Resti M, Azzari C, Rossi ME, et al. Five-year follow-up of vaccination against hepatitis B virus in newborns vaccinated with a reduced number of doses. Vaccine. 1991;9:15-18.
23. Wang CW, Wang LC, Chang MH, et al. Long-term follow-up of Hepatitis B Surface antibody levels in subjects receiving universal Hepatitis B vaccination in infancy in an area of hyperendemicity: correlation between radioimmunoassay and enzyme immunoassay. Clin Diagn Lab Immunol. 2005;12:1442-1447.
24. Zanetti AR, Mariano A, Romanò L, et al.; Study Group. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005;366:1379-1384.
25. Zanetti AR, Romanò L, Giambi C, et al.; study group. Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study. Lancet Infect Dis. 2010;10:755-761.
26. Zhu CL, Liu P, Chen T, et al. Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination. Vaccine. 2011;29:7835-7841.
27. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine. 2000;19:877-885.
28. Dentinger CM, McMahon BJ, Butler JC, et al. Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth. Pediatr Infect Dis J. 2005;24:786-792.
29. Hammitt LL, Hennessy TW, Fiore AE, et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine. 2007;25:6958-6964.
30. Poovorawan Y, Chongsrisawat V, Theamboonlers A, et al. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine. 2010;28:730-736.
31. Belloni C, Pistorio A, Tinelli C, et al. Early immunisation with hepatitis B vaccine: a five-year study. Vaccine. 2000;18:1307-1311.
32. Petersen KM, Bulkow LR, McMahon BJ, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J. 2004;23:650-655.
33. Samandari T, Fiore AE, Negus S, et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics. 2007;120:e373-e381.
34. Da Villa G, Peluso F, Picciotto L, et al. Persistence of anti-HBs in children vaccinated against viral hepatitis B in the first year of life: follow-up at 5 and 10 years. Vaccine. 1996;14:1503-1505.
35. Lu CY, Chiang BL, Chi WK, et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology. 2004;40:1415-1420.
36. Williams IT, Goldstein ST, Tufa J, et al. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatr Infect Dis J. 2003;22:157-163.
37. Yuen MF, Lim WL, Cheng CC, et al. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. Hepatology. 1999;29:924-927.
38. Marion SA, Tomm Pastore M, Pi DW, et al. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol. 1994;140: 734-746.
39. Centers for Disease Control and Prevention. Yellow Book: Infectious diseases related to travel (Chapter 3). Available at: http://wwwnc.cdc.gov/ travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/ hepatitis-b.htm. Accessed November 11, 2011.
40. Merkel S, Mansmann U, Hohenberger W, et al. Time to locoregional recurrence after curative resection of rectal carcinoma is prolonged after neoadjuvant treatment: a systematic review and meta-analysis. Colorectal Dis. 2011;13:123-131.
41. Crowther MJ, Abrams KR, Lambert PC. Flexible parametric joint modelling of longitudinal and survival data. Stat Med. 2012;31:4456-4471.
42. Jackson R, Ameratunga S, Broad J, et al. The GATE frame: critical appraisal with pictures. Evid Based Med. 2006;11:35-38.
43. Ding L, Zhang M, Wang Y, et al. A 9-year follow-up study of the immuno-genicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates. Clin Infect Dis. 1993;17:475-479.
44. Jilg W, Schmidt M, Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis. 1989;160:766-769.
45. McBean AM, Thorns ML, Albrecht P, et al. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Am J Epidemiol. 1988;128:615-628.
46. Van Damme P, Matheï C, Thoelen S, et al. Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. J Med Virol. 1994;44:435-441.
47. Rosado MM, Scarsella M, Pandolfi E, et al. Switched memory B cells maintain specific memory independently of serum antibodies: the hepatitis B example. Eur J Immunol. 2011;41:1800-1808.
48. Mele A, Tancredi F, Romano L, et al. Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy. J Infect Dis. 2001;184:905-908.
49. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
50. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-2012.
51. Smith TC, Spiegelhalter DJ, Thomas A. Bayesian approaches to random-effects meta-analysis: a comparative study. Stat Med. 1995;14:2685-2699.
52. Spiegelhalter D, Abrams K, Myles J. Bayesian Approaches to Clinical Trials and Health-Care Evaluation: Chichester: John Wiley & Sons; 2004.
53. Whittle H, Jaffar S, Wansbrough M, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 2002;325:569.
54. Gesemann M, Scheiermann N. Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence. Vaccine. 1995;13:443-447.
55. Alfaleh F, Alshehri S, Alansari S, et al. Long-term protection of hepatitis B vaccine 18 years after vaccination. J Infect. 2008;57:404-409.
56. Faustini A, Franco E, Sangalli M, et al. Persistence of anti-HBs 5 years after the introduction of routine infant and adolescent vaccination in Italy. Vaccine. 2001;19:2812-2818.
57. Hadi N, Hadi N. Assessment of anti-HBs antigen in 6-to 9-year-old children routinely vaccinated via vaccination program in Iran. MedPrinc Pract. 2007;16:306-309.
58. Hashemi S, Moghadami M, Lankarani K, et al. The efficacy of hepatitis B vaccination. Iran Red Crescent Med J. 2010;12:45-48.
59. Jaber SM. Prevalence of anti-hepatitis B and anti-hepatitis A antibodies among school aged children in Western Saudi Arabia. Saudi Med J. 2006;27:1515-1522.
60. Jafarzadeh A, Sajjadi SMA. Persistence of anti-HBs antibodies in healthy Iranian children vaccinated with recombinant hepatitis B vaccine and response to a booster dose. Acta Medica Iranica 2005;43: 79-84.
61. Jafarzadeh A, Montazerifar SJ. Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth. J Ayub Med Coll Abbottabad. 2006;18:4-9.
62. Livramento Ad, Cordova CM, Scaraveli NG, et al. Anti-HBs levels among children and adolescents with complete immunization schedule against hepatitis B virus. A cross-sectional study in Blumenau, State of Santa Catarina, Brazil, 2007-2008. Rev Soc Bras Med Trop. 2011;44:412-415.
63. Ochirbat T, Ali M, Pagbajab N, et al. Assessment of hepatitis B vaccine-induced seroprotection among children 5-10 years old in Ulaanbaatar, Mongolia. Biosci Trends. 2008;2:68-74.
64. Odusanya OO, Alufohai E, Meurice FP, et al. Five-year post vaccination efficacy of hepatitis B vaccine in rural Nigeria. Hum Vaccin. 2011;7: 625-629.
65. Saffar MJ, Rezai MS. Long-term antibody response and immunologic memory in children immunized with hepatitis B vaccine at birth. Indian Pediatr. 2004;41:1232-1237.
66. Shaaban FA, Hassanin AI, Samy SM, et al. Long-term immunity to hepatitis B among a sample of fully vaccinated children in Cairo, Egypt. East Mediterr Health J. 2007;13:750-757.
67. Shamsizadeh A, Makvandi M, Shoshtari G. Prevalence of anti hepatitis B surface antibody among children in Ahvaz, Iran, five years after vaccination. Jundishapur J Microbiol. 2011;4:49-54.
68. Shih HH, Chang MH, Hsu HY, et al. Long term immune response of universal hepatitis B vaccination in infancy: a community-based study in Taiwan. Pediatr Infect Dis J. 1999;18:427-432.
69. Su FH, Cheng SH, Li CY, et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine. 2007;25:8085-8090.
70. Yazdanpanah B, Safari M, Yazdanpanah S. Persistence of HBV vaccine's protection and response to hepatitis B booster immunization in 5-to 7-year-old children in the Kohgiloyeh and Boyerahmad Province, Iran. Hepat Mon. 2010;10:17-21.
71. Jan CF, Huang KC, Chien YC, et al. Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology. 2010;51:1547-1554.
72. Reinert P, Cinquetti S, Soubeyrand B, et al. Challenge with hepatitis B vaccine in children previously vaccinated with a hepatitis B-containing combination vaccine. Adv Ther. 2010;27:28-38.
73. Wang LY, Lin HH. Short-term response to a booster dose of hepatitis B vaccine in anti-HBs negative adolescents who had received primary vaccination 16 years ago. Vaccine. 2007;25:7160-7167.
74. Yao J, Ren J, Shen L, et al. The effects of booster vaccination of hepatitis B vaccine on anti-HBV surface antigen negative children 11-15 years after primary vaccination. Hum Vaccin. 2011;7:1055-1059.